Do TP53 mutations affect Azacitidine and DCI effectiveness

TP53 Mutations and Azacitidine/DCI Effectiveness in MDS

TL;DR: TP53 mutations can reduce how well azacitidine works in MDS, but decitabine-cedazuridine (DCI) and combination therapies may still help—your specific mutation type and disease context matter more than the mutation alone.

KEY POINTS:

• TP53 mutations are a poor prognostic marker in MDS and are associated with shorter survival and higher risk of transformation to AML, regardless of treatment
• Azacitidine response rates drop significantly in TP53-mutant MDS (roughly 20-30% response vs. 40-50% in TP53 wild-type), but some patients still respond
• Decitabine-cedazuridine (DCI) may offer an alternative with potentially different efficacy patterns, though head-to-head data in TP53-mutant disease is limited
• Combination approaches (hypomethylating agents + venetoclax, or + targeted therapies) show promise in TP53-mutant MDS post-transplant
• Your del(7q) and DNMT3A mutation context matters—these interact with TP53 status to influence prognosis and treatment selection

NEXT STEP: Ask your hematologist whether your specific TP53 mutation status was tested, what the variant allele frequency (VAF) is, and whether combination therapy or DCI should be considered given your post-transplant relapse.

---

FULL ANSWER

Standard-of-Care Context: TP53 Mutations in MDS

According to the NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026), TP53 mutations are recognized as a high-risk molecular feature that significantly impacts prognosis and treatment response. Here's what the evidence shows:

1. TP53 as a Prognostic Marker

TP53 mutations are classified as a poor-risk cytogenetic/molecular feature in the IPSS-R and newer molecular prognostic scoring systems (IPSS-M). The NCCN guidelines note that:

• Patients with biallelic TP53 inactivation (two mutated copies) have particularly poor outcomes
• Even monoallelic TP53 mutations (one mutated copy) are associated with:
  • Shorter median overall survival (typically 6-12 months without intensive treatment)
  • Higher rates of AML transformation (25-50% within 1-2 years)
  • Reduced response to standard hypomethylating agents (HMAs)

Your case is relevant here: you have relapsed therapy-related MDS (tMDS) post-allogeneic stem cell transplant, which already carries higher risk. If TP53 is mutated, this compounds the risk profile.

2. Azacitidine Response in TP53-Mutant MDS

The clinical data on azacitidine efficacy in TP53-mutant MDS shows:

Response Rates:

• TP53 wild-type MDS: 40-50% overall response rate (ORR) to azacitidine
• TP53-mutant MDS: 15-30% ORR, with shorter duration of response
• TP53 biallelic inactivation: <10% ORR in some series

Why the difference?

• TP53 mutations impair the tumor suppressor's ability to trigger apoptosis (cell death) in response to DNA-damaging agents like azacitidine
• Azacitidine works partly by inducing DNA damage and p53-mediated cell death—if p53 is broken, this mechanism is blunted
• TP53-mutant cells are often more chemotherapy-resistant and prone to rapid clonal evolution

Duration of Response:

• Patients with TP53 mutations who do respond to azacitidine typically have shorter progression-free survival (median 4-8 months vs. 12-18 months in TP53 wild-type)

3. Decitabine-Cedazuridine (DCI) in TP53-Mutant Disease

Decitabine-cedazuridine is an oral formulation combining decitabine (a hypomethylating agent similar to azacitidine) with cedazuridine (a cytidine deaminase inhibitor that improves drug bioavailability).

NCCN Recommendation: The NCCN Guidelines note that DCI could be a substitution for intravenous decitabine in patients with IPSS Intermediate-1 and above, particularly for those who need oral dosing or have difficulty with IV access.

In TP53-Mutant MDS:

• Direct head-to-head comparisons in TP53-mutant disease are limited
• Decitabine and azacitidine have similar mechanisms, so TP53 status likely affects both similarly
• However, some data suggest decitabine may have slightly different pharmacokinetics and could be worth trying if azacitidine fails
• The oral formulation (DCI) may improve adherence and allow for dose optimization

---

Beyond Standard Guidelines: Emerging Approaches for TP53-Mutant MDS

1. Combination Therapies: HMA + Venetoclax

Azacitidine + Venetoclax (V2) is increasingly used in TP53-mutant MDS, particularly post-transplant:

• Mechanism: Azacitidine primes cells for apoptosis; venetoclax (a BCL-2 inhibitor) delivers the "kill signal" by blocking anti-apoptotic proteins
• Advantage in TP53-mutant disease: Bypasses the need for functional p53 by using an alternative apoptosis pathway
• Your context: You've already completed azacitidine + venetoclax. The question is whether this combination should be re-used, continued, or escalated if you relapse again

Evidence:

• In TP53-mutant MDS, combination HMA + venetoclax shows higher response rates (40-60%) than HMA alone
• Median overall survival in TP53-mutant patients on HMA + venetoclax is approximately 12-18 months (vs. 6-12 months on HMA monotherapy)

2. TP53-Targeted Therapies (Investigational)

Several approaches are in clinical trials for TP53-mutant MDS:

A. MDM2 Inhibitors (e.g., idasanutlin, APG-115)

• Mechanism: MDM2 normally suppresses p53; blocking MDM2 can reactivate even mutant p53 in some contexts
• Status: Phase I/II trials in MDS
• Rationale: May restore some p53 function or sensitize cells to other therapies

B. p53 Reactivation Agents (e.g., PRIMA-1, APR-246)

• Mechanism: Restore wild-type conformation to mutant p53 proteins
• Status: APR-246 is in Phase II/III trials for TP53-mutant MDS in combination with azacitidine
• Preliminary data: Combination APR-246 + azacitidine shows improved response rates in TP53-mutant MDS compared to azacitidine alone
• Relevance to you: If available through clinical trial, this could be worth exploring

C. Checkpoint Inhibitors (e.g., nivolumab, pembrolizumab)

• Rationale: TP53-mutant MDS often has high tumor mutational burden (TMB) and may respond to immune checkpoint inhibition
• Status: Early-phase trials; not yet standard of care
• Caution: Post-transplant patients have unique immune reconstitution; checkpoint inhibitors carry risk of graft-versus-host disease (GVHD)

3. Targeted Therapies Based on Co-Mutations

Your mutation profile includes DNMT3A (R882H) and del(7q). These interact with TP53 status:

DNMT3A Mutations:

• DNMT3A-mutant MDS may respond to IDH inhibitors (ivosidenib, enasidenib) if IDH1/IDH2 mutations are also present
• If not, DNMT3A-mutant disease is often treated with HMA + venetoclax (which you've done)

del(7q) Context:

• del(7q) is a poor-risk cytogenetic feature that compounds TP53 risk
• Patients with del(7q) + TP53 mutations have particularly aggressive disease
• NCCN recommendation: Consider allogeneic hematopoietic cell transplant (HCT) as consolidation if in remission
• You've already had allo-HSCT; the relapse suggests the disease is chemotherapy-resistant and may require more aggressive salvage approaches

4. Salvage Strategies Post-Relapse

Given that you've relapsed after allo-HSCT and completed azacitidine + venetoclax, options include:

A. Repeat HMA + Venetoclax (with dose escalation or extended duration)

• Some patients benefit from re-induction if there was an initial response
• Dose escalation of venetoclax (up to 800 mg daily) may improve efficacy

B. Switch to Decitabine-Cedazuridine (DCI)

• If azacitidine was used, DCI offers an alternative HMA with potentially better bioavailability
• May be combined with venetoclax or other agents

C. Investigational Agents (Clinical Trials)

• Aurora kinase A inhibitors (you've noted these as investigational in your profile)

  • Mechanism: Target cell cycle and mitotic checkpoints; may be effective in TP53-mutant disease
  • Status: Phase I/II trials
  • Rationale: TP53-mutant cells often have mitotic instability; aurora kinase inhibition may exploit this

• Adavosertib (MK-1775) (also noted in your profile)

  • Mechanism: Wee1 kinase inhibitor; prevents G2/M checkpoint, forcing TP53-mutant cells into mitosis and apoptosis
  • Status: Phase I/II trials in MDS
  • Rationale: Particularly promising in TP53-mutant disease because it bypasses p53-dependent checkpoints
  • Combination potential: Adavosertib + azacitidine or + decitabine shows synergy in preclinical models

D. Second Allogeneic Transplant

• In highly selected patients with TP53-mutant relapsed MDS post-first allo-HSCT
• Requires careful evaluation of performance status, donor availability, and disease burden
• Median survival post-second transplant is typically 6-12 months

---

Your Specific Context: Relapsed tMDS with del(7q) + DNMT3A + TP53 (if present)

Key Questions to Ask Your Hematologist:

1. TP53 mutation status: Do you have a TP53 mutation? If so:

   • What is the specific mutation (missense, frameshift, nonsense)?
   • What is the variant allele frequency (VAF)?
   • Is it monoallelic or biallelic?

2. Azacitidine response: Did you have a response to azacitidine + venetoclax before relapse?

   • If yes: Consider re-induction or escalation
   • If no: Consider alternative HMA (DCI) or investigational agents

3. Clinical trial eligibility: Are you eligible for trials of:

   • APR-246 (p53 reactivator) + azacitidine
   • Adavosertib (Wee1 inhibitor) + HMA
   • Aurora kinase A inhibitors
   • MDM2 inhibitors

4. Transplant status: Given your relapse post-allo-HSCT:

   • Is there evidence of graft-versus-leukemia (GVL) effect?
   • Could donor lymphocyte infusion (DLI) be considered?
   • Is a second transplant feasible?

---

Summary: TP53 Mutations and Treatment Efficacy

| Feature | TP53 Wild-Type | TP53-Mutant | |---|---|---| | Azacitidine ORR | 40-50% | 15-30% | | Median OS on HMA | 12-18 months | 6-12 months | | HMA + Venetoclax ORR | 50-60% | 40-60% | | Median OS on HMA + Venetoclax | 18-24 months | 12-18 months | | Best approach | HMA monotherapy or + venetoclax | Combination therapy; consider investigational agents |

---

Evidence Sources

• NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026): Prognostic scoring systems, TP53 as poor-risk feature, treatment recommendations for HMA-resistant disease
• Cancer Patient Lab Webinars: Discussions on precision oncology, molecular profiling, and treatment selection in advanced MDS
• Published literature: TP53 mutations as predictors of HMA response; combination HMA + venetoclax efficacy; emerging TP53-targeted therapies

---

NEXT STEPS

1. Confirm TP53 status with your hematologist if not already done
2. Review your azacitidine + venetoclax response (duration, depth of response)
3. Explore clinical trial eligibility for TP53-targeted agents or investigational combinations
4. Discuss salvage options with your transplant team, including DCI, dose escalation, or second transplant consideration

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about your specific treatment plan.